Abstract

Sleep-wake disturbances are common in neurodegenerative diseases and may occur years before the clinical diagnosis, potentially either representing an early stage of the disease itself or acting as a pathophysiological driver. Therefore, discovering biomarkers that identify individuals with sleep-wake disturbances who are at risk of developing neurodegenerative diseases will allow early diagnosis and intervention. Given the association between sleep and neurodegeneration, the most frequently analyzed fluid biomarkers in people with sleep-wake disturbances to date include those directly associated with neurodegeneration itself, such as neurofilament light chain, phosphorylated tau, amyloid-beta and alpha-synuclein. Abnormalities in these biomarkers in patients with sleep-wake disturbances are considered as evidence of an underlying neurodegenerative process. Levels of hormonal sleep-related biomarkers such as melatonin, cortisol and orexin are often abnormal in patients with clinical neurodegenerative diseases, but their relationships with the more standard neurodegenerative biomarkers remain unclear. Similarly, it is unclear whether other chronobiological/circadian biomarkers, such as disrupted clock gene expression, are causal factors or a consequence of neurodegeneration. Current data would suggest that a combination of fluid biomarkers may identify sleep-wake disturbances that are most predictive for the risk of developing neurodegenerative disease with more optimal sensitivity and specificity.

Keywords

Biomarkers, Dementia, Neurodegenerative diseases, Sleep-wake disturbances

Document Type

Journal Article

Date of Publication

1-1-2024

Article Number

106369

Volume

190

PubMed ID

38049012

Publication Title

Neurobiology of Disease

Publisher

Elsevier

School

School of Medical and Health Sciences

RAS ID

64685

Funding Information

This work is supported by the NHMRC Centre of Research Excellence to Optimize Brain Ageing in Neurodegeneration (CogSleep CRE). Dr. Yang and Dr. Michaelian are supported by a CogSleep CRE Fellowship. Prof Naismith and A/Prof Craig Phillips are supported by a Boosting Dementia Leadership Fellowship. Dr. D'Rozario is supported by an NHMRC-ARC Dementia Fellowship. Prof Lewis is supported by an NHMRC Leadership Fellowship. G.M.H. and R.G are supported by NHMRC Senior Leadership Fellowships. G.M.H. and W.S.K. are supported by funding to ForeFront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neuron disease, from the National Health and Medical Research Council of Australia (NHMRC) program grant (#1037746).

Funding received from the National Health and Medical Research Council (NHMRC)

1037746

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Comments

Yang, Y., Kim, W. S., Michaelian, J, C., Lewis, S. J. G., Phillips, C. L., D'Rozario, A. L., . . . Naismith, S. L. (2024). Predicting neurodegeneration from sleep related biofluid changes. Neurobiology of Diseases, 190, article 106369. https://doi.org/10.1016/j.nbd.2023.106369

Content Type

Full object

Recommended Citation

Yang, Y., Kim, W. S., Michaelian, J, C., Lewis, S. J. G., Phillips, C. L., D'Rozario, A. L., . . . Naismith, S. L. (2024). Predicting neurodegeneration from sleep related biofluid changes. Neurobiology of Diseases, 190, Article 106369. https://doi.org/10.1016/j.nbd.2023.106369

Download

Included in

Neurosciences Commons

Share

 
COinS
 

Link to publisher version (DOI)

10.1016/j.nbd.2023.106369